Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Phenylalanine hydroxylase genotype-phenotype associations in the United States: A single center study.

Rajabi F, Rohr F, Wessel A, Martell L, Dobrowolski SF, Guldberg P, Güttler F, Levy HL.

Mol Genet Metab. 2019 Dec;128(4):415-421. doi: 10.1016/j.ymgme.2019.09.004. Epub 2019 Sep 14.

PMID:
31623983
2.

Evaluating the Role of RARβ Signaling on Cellular Metabolism in Melanoma Using the Seahorse XF Analyzer.

Dahl C, Guldberg P, Abildgaard C.

Methods Mol Biol. 2019;2019:171-180. doi: 10.1007/978-1-4939-9585-1_12.

PMID:
31359396
3.

DNA-Methylation-Based Detection of Urological Cancer in Urine: Overview of Biomarkers and Considerations on Biomarker Design, Source of DNA, and Detection Technologies.

Larsen LK, Lind GE, Guldberg P, Dahl C.

Int J Mol Sci. 2019 May 30;20(11). pii: E2657. doi: 10.3390/ijms20112657. Review.

4.

Adoptive T cell cancer therapy.

Dzhandzhugazyan KN, Guldberg P, Kirkin AF.

Nat Mater. 2018 Jun;17(6):475-477. doi: 10.1038/s41563-018-0094-5. No abstract available.

PMID:
29795224
5.

Noninvasive Detection of High Grade Prostate Cancer by DNA Methylation Analysis of Urine Cells Captured by Microfiltration.

Larsen LK, Jakobsen JS, Abdul-Al A, Guldberg P.

J Urol. 2018 Oct;200(4):749-757. doi: 10.1016/j.juro.2018.04.067. Epub 2018 Apr 24.

PMID:
29702096
6.

Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells.

Kirkin AF, Dzhandzhugazyan KN, Guldberg P, Fang JJ, Andersen RS, Dahl C, Mortensen J, Lundby T, Wagner A, Law I, Broholm H, Madsen L, Lundell-Ek C, Gjerstorff MF, Ditzel HJ, Jensen MR, Fischer W.

Nat Commun. 2018 Mar 6;9(1):785. doi: 10.1038/s41467-018-03217-9.

7.

Inhibition of retinoic acid receptor β signaling confers glycolytic dependence and sensitization to dichloroacetate in melanoma cells.

Abildgaard C, Dahl C, Abdul-Al A, Christensen A, Guldberg P.

Oncotarget. 2017 Aug 24;8(48):84210-84223. doi: 10.18632/oncotarget.20476. eCollection 2017 Oct 13.

8.

Simultaneous Profiling of DNA Mutation and Methylation by Melting Analysis Using Magnetoresistive Biosensor Array.

Rizzi G, Lee JR, Dahl C, Guldberg P, Dufva M, Wang SX, Hansen MF.

ACS Nano. 2017 Sep 26;11(9):8864-8870. doi: 10.1021/acsnano.7b03053. Epub 2017 Sep 13.

9.

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.

Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano-Almendras CP, Husby S, Freiburghaus C, Ek S, Pedersen A, Niemann C, Räty R, Brown P, Geisler CH, Andersen MK, Guldberg P, Jerkeman M, Grønbæk K.

Blood. 2017 Oct 26;130(17):1903-1910. doi: 10.1182/blood-2017-04-779736. Epub 2017 Aug 17.

PMID:
28819011
10.

Experimental factors affecting the robustness of DNA methylation analysis.

Pharo HD, Honne H, Vedeld HM, Dahl C, Andresen K, Liestøl K, Jeanmougin M, Guldberg P, Lind GE.

Sci Rep. 2016 Sep 27;6:33936. doi: 10.1038/srep33936.

11.

Denaturation strategies for detection of double stranded PCR products on GMR magnetic biosensor array.

Rizzi G, Lee JR, Guldberg P, Dufva M, Wang SX, Hansen MF.

Biosens Bioelectron. 2017 Jul 15;93:155-160. doi: 10.1016/j.bios.2016.09.031. Epub 2016 Sep 12.

PMID:
27650710
12.

A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria.

Dahmcke CM, Steven KE, Larsen LK, Poulsen AL, Abdul-Al A, Dahl C, Guldberg P.

Eur Urol. 2016 Dec;70(6):916-919. doi: 10.1016/j.eururo.2016.06.035. Epub 2016 Jul 11.

PMID:
27417036
13.

Genome-wide DNA methylation analysis of transient neonatal diabetes type 1 patients with mutations in ZFP57.

Bak M, Boonen SE, Dahl C, Hahnemann JM, Mackay DJ, Tümer Z, Grønskov K, Temple IK, Guldberg P, Tommerup N.

BMC Med Genet. 2016 Apr 14;17:29. doi: 10.1186/s12881-016-0292-4.

14.

BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions.

Larsen AC, Dahl C, Dahmcke CM, Lade-Keller J, Siersma VD, Toft PB, Coupland SE, Prause JU, Guldberg P, Heegaard S.

Acta Ophthalmol. 2016 Aug;94(5):463-70. doi: 10.1111/aos.13007. Epub 2016 Mar 24.

15.

A Retrospective Review of Conjunctival Melanoma Presentation, Treatment, and Outcome and an Investigation of Features Associated With BRAF Mutations.

Larsen AC, Dahmcke CM, Dahl C, Siersma VD, Toft PB, Coupland SE, Prause JU, Guldberg P, Heegaard S.

JAMA Ophthalmol. 2015 Nov;133(11):1295-303. doi: 10.1001/jamaophthalmol.2015.3200.

PMID:
26425792
16.

Filtration Device for On-Site Collection, Storage and Shipment of Cells from Urine and Its Application to DNA-Based Detection of Bladder Cancer.

Andersson E, Dahmcke CM, Steven K, Larsen LK, Guldberg P.

PLoS One. 2015 Jul 7;10(7):e0131889. doi: 10.1371/journal.pone.0131889. eCollection 2015.

17.

S100A4-neutralizing antibody suppresses spontaneous tumor progression, pre-metastatic niche formation and alters T-cell polarization balance.

Grum-Schwensen B, Klingelhöfer J, Beck M, Bonefeld CM, Hamerlik P, Guldberg P, Grigorian M, Lukanidin E, Ambartsumian N.

BMC Cancer. 2015 Feb 12;15:44. doi: 10.1186/s12885-015-1034-2.

18.

DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells.

Nordström L, Andersson E, Kuci V, Gustavsson E, Holm K, Ringnér M, Guldberg P, Ek S.

BMC Cancer. 2015 Apr 12;15:273. doi: 10.1186/s12885-015-1208-y.

19.

Molecular drivers of cellular metabolic reprogramming in melanoma.

Abildgaard C, Guldberg P.

Trends Mol Med. 2015 Mar;21(3):164-71. doi: 10.1016/j.molmed.2014.12.007. Epub 2015 Jan 21. Review.

PMID:
25618774
20.

Persistence of DNMT3A mutations at long-term remission in adult patients with AML.

Pløen GG, Nederby L, Guldberg P, Hansen M, Ebbesen LH, Jensen UB, Hokland P, Aggerholm A.

Br J Haematol. 2014 Nov;167(4):478-86. doi: 10.1111/bjh.13062. Epub 2014 Aug 4.

PMID:
25371149
21.

A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility.

Christensen C, Bartkova J, Mistrík M, Hall A, Lange MK, Ralfkiær U, Bartek J, Guldberg P.

Nat Commun. 2014 Nov 5;5:5348. doi: 10.1038/ncomms6348.

PMID:
25370744
22.

Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition.

Abildgaard C, Dahl C, Basse AL, Ma T, Guldberg P.

J Transl Med. 2014 Sep 3;12:247. doi: 10.1186/s12967-014-0247-5.

23.

KIT is a frequent target for epigenetic silencing in cutaneous melanoma.

Dahl C, Abildgaard C, Riber-Hansen R, Steiniche T, Lade-Keller J, Guldberg P.

J Invest Dermatol. 2015 Feb;135(2):516-524. doi: 10.1038/jid.2014.372. Epub 2014 Sep 1.

24.

Epigenetic remodelling and dysregulation of DLGAP4 is linked with early-onset cerebellar ataxia.

Minocherhomji S, Hansen C, Kim HG, Mang Y, Bak M, Guldberg P, Papadopoulos N, Eiberg H, Doh GD, Møllgård K, Hertz JM, Nielsen JE, Ropers HH, Tümer Z, Tommerup N, Kalscheuer VM, Silahtaroglu A.

Hum Mol Genet. 2014 Dec 1;23(23):6163-76. doi: 10.1093/hmg/ddu337. Epub 2014 Jul 1.

25.

Mitochondrial DNA copy number and future risk of B-cell lymphoma in a nested case-control study in the prospective EPIC cohort.

Hosnijeh FS, Lan Q, Rothman N, San Liu C, Cheng WL, Nieters A, Guldberg P, Tjønneland A, Campa D, Martino A, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Krogh V, Tumino R, Panico S, Masala G, Weiderpass E, Huerta Castaño JM, Ardanaz E, Sala N, Dorronsoro M, Quirós JR, Sánchez MJ, Melin B, Johansson AS, Malm J, Borgquist S, Peeters PH, Bueno-de-Mesquita HB, Wareham N, Khaw KT, Travis RC, Brennan P, Siddiq A, Riboli E, Vineis P, Vermeulen R.

Blood. 2014 Jul 24;124(4):530-5. doi: 10.1182/blood-2013-10-532085. Epub 2014 Jun 4.

26.

Resting brain perfusion and selected vascular risk factors in healthy elderly subjects.

Henriksen OM, Jensen LT, Krabbe K, Guldberg P, Teerlink T, Rostrup E.

PLoS One. 2014 May 19;9(5):e97363. doi: 10.1371/journal.pone.0097363. eCollection 2014.

27.

Prediagnostic telomere length and risk of B-cell lymphoma-Results from the EPIC cohort study.

Hosnijeh FS, Matullo G, Russo A, Guarrera S, Modica F, Nieters A, Overvad K, Guldberg P, Tjønneland A, Canzian F, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Trichopoulos D, Tagliabue G, Tumino R, Panico S, Palli D, Olsen KS, Weiderpass E, Dorronsoro M, Ardanaz E, Chirlaque MD, Sánchez MJ, Quirós JR, Venceslá A, Melin B, Johansson AS, Nilsson P, Borgquist S, Peeters PH, Onland-Moret NC, Bueno-de-Mesquita HB, Travis RC, Khaw KT, Wareham N, Brennan P, Ferrari P, Gunter MJ, Vineis P, Vermeulen R.

Int J Cancer. 2014 Dec 15;135(12):2910-7. doi: 10.1002/ijc.28934. Epub 2014 May 12.

28.

Size-based enrichment of exfoliated tumor cells in urine increases the sensitivity for DNA-based detection of bladder cancer.

Andersson E, Steven K, Guldberg P.

PLoS One. 2014 Apr 14;9(4):e94023. doi: 10.1371/journal.pone.0094023. eCollection 2014.

29.

Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.

Lade-Keller J, Riber-Hansen R, Guldberg P, Schmidt H, Hamilton-Dutoit SJ, Steiniche T.

J Clin Pathol. 2014 Jun;67(6):520-8. doi: 10.1136/jclinpath-2013-202127. Epub 2014 Mar 7.

PMID:
24607493
30.

Author's reply: To PMID 23159593.

Kristensen LS, Hansen LL, Lade-Keller J, Riber-Hansen R, Steiniche T, Hager H, Guldberg P.

J Mol Diagn. 2013 Jul;15(4):536-7. No abstract available.

PMID:
23957053
31.

Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARβ signaling.

Dahl C, Christensen C, Jönsson G, Lorentzen A, Skjødt ML, Borg Å, Pawelec G, Guldberg P.

Mol Cancer Res. 2013 Oct;11(10):1166-78. doi: 10.1158/1541-7786.MCR-13-0006. Epub 2013 Jul 12.

32.

The challenges of comparing a clinically validated test to other methods.

Palma JF, Shieh F, Kristensen LS, Hansen LL, Lade-Keller J, Riber-Hansen R, Steiniche T, Hager H, Guldberg P.

J Mol Diagn. 2013 Jul;15(4):535-7. doi: 10.1016/j.jmoldx.2013.02.007. No abstract available.

PMID:
23791447
33.

E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression.

Lade-Keller J, Riber-Hansen R, Guldberg P, Schmidt H, Hamilton-Dutoit SJ, Steiniche T.

Br J Dermatol. 2013 Sep;169(3):618-28. doi: 10.1111/bjd.12426.

PMID:
23662813
34.

Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene.

Hall A, Meyle KD, Lange MK, Klima M, Sanderhoff M, Dahl C, Abildgaard C, Thorup K, Moghimi SM, Jensen PB, Bartek J, Guldberg P, Christensen C.

Oncotarget. 2013 Apr;4(4):584-99.

35.

Aberrantly methylated DNA as a biomarker in breast cancer.

Kristiansen S, Jørgensen LM, Guldberg P, Sölétormos G.

Int J Biol Markers. 2013 Apr-Jun;28(2):141-50. doi: 10.5301/jbm.5000009. Epub 2013 Apr 2.

PMID:
23564623
36.

A role for immunohistochemical detection of BRAF V600E prior to BRAF-inhibitor treatment of malignant melanoma?

Lade-Keller J, Kristensen LS, Riber-Hansen R, Guldberg P, Hansen LL, Steiniche T, Hager H.

J Clin Pathol. 2013 Aug;66(8):723-5. doi: 10.1136/jclinpath-2013-201483. Epub 2013 Mar 23. No abstract available.

PMID:
23526598
37.

Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.

Lade-Keller J, Rømer KM, Guldberg P, Riber-Hansen R, Hansen LL, Steiniche T, Hager H, Kristensen LS.

J Mol Diagn. 2013 Jan;15(1):70-80. doi: 10.1016/j.jmoldx.2012.08.003. Epub 2012 Nov 14.

38.

Oncogenic events associated with endometrial and ovarian cancers are rare in endometriosis.

Vestergaard AL, Thorup K, Knudsen UB, Munk T, Rosbach H, Poulsen JB, Guldberg P, Martensen PM.

Mol Hum Reprod. 2011 Dec;17(12):758-61. doi: 10.1093/molehr/gar049. Epub 2011 Jun 30.

PMID:
21724579
39.

Role of fibulin-5 in metastatic organ colonization.

Møller HD, Ralfkjær U, Cremers N, Frankel M, Pedersen RT, Klingelhöfer J, Yanagisawa H, Grigorian M, Guldberg P, Sleeman J, Lukanidin E, Ambartsumian N.

Mol Cancer Res. 2011 May;9(5):553-63. doi: 10.1158/1541-7786.MCR-11-0093. Epub 2011 Mar 31.

40.

Advances in DNA methylation: 5-hydroxymethylcytosine revisited.

Dahl C, Grønbæk K, Guldberg P.

Clin Chim Acta. 2011 May 12;412(11-12):831-6. doi: 10.1016/j.cca.2011.02.013. Epub 2011 Feb 12. Review.

PMID:
21324307
41.

Germline minisatellite mutations in survivors of childhood and young adult cancer treated with radiation.

Tawn EJ, Rees GS, Leith C, Winther JF, Curwen GB, Stovall M, Olsen JH, Rechnitzer C, Schroeder H, Guldberg P, Boice JD.

Int J Radiat Biol. 2011 Mar;87(3):330-40. doi: 10.3109/09553002.2011.530338. Epub 2010 Nov 19.

42.

Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.

Serizawa RR, Ralfkiaer U, Steven K, Lam GW, Schmiedel S, Schüz J, Hansen AB, Horn T, Guldberg P.

Int J Cancer. 2011 Jul 1;129(1):78-87. doi: 10.1002/ijc.25651. Epub 2010 Nov 3.

43.

The heritability of G2 chromosomal radiosensitivity and its association with cancer in Danish cancer survivors and their offspring.

Curwen GB, Cadwell KK, Winther JF, Tawn EJ, Rees GS, Olsen JH, Rechnitzer C, Schroeder H, Guldberg P, Cordell HJ, Boice JD Jr.

Int J Radiat Biol. 2010 Nov;86(11):986-95. doi: 10.3109/09553002.2010.496027. Epub 2010 Sep 1.

44.

Custom-designed MLPA using multiple short synthetic probes: application to methylation analysis of five promoter CpG islands in tumor and urine specimens from patients with bladder cancer.

Serizawa RR, Ralfkiaer U, Dahl C, Lam GW, Hansen AB, Steven K, Horn T, Guldberg P.

J Mol Diagn. 2010 Jul;12(4):402-8. doi: 10.2353/jmoldx.2010.090152. Epub 2010 Apr 22.

45.

Genetic risk factors for melanoma.

Meyle KD, Guldberg P.

Hum Genet. 2009 Oct;126(4):499-510. doi: 10.1007/s00439-009-0715-9. Epub 2009 Jul 8. Review.

PMID:
19585149
46.

Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy.

Grønbaek K, Treppendahl M, Asmar F, Guldberg P.

Basic Clin Pharmacol Toxicol. 2008 Nov;103(5):389-96. doi: 10.1111/j.1742-7843.2008.00325.x. Review.

47.

Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms.

Grønbaek K, Ralfkiaer U, Dahl C, Hother C, Burns JS, Kassem M, Worm J, Ralfkiaer EM, Knudsen LM, Hokland P, Guldberg P.

Mod Pathol. 2008 May;21(5):632-8. doi: 10.1038/modpathol.2008.27. Epub 2008 Feb 8.

48.

Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.

Mellemkjaer L, Dahl C, Olsen JH, Bertelsen L, Guldberg P, Christensen J, Børresen-Dale AL, Stovall M, Langholz B, Bernstein L, Lynch CF, Malone KE, Haile RW, Andersson M, Thomas DC, Concannon P, Capanu M, Boice JD Jr; WECARE Study Collaborative Group, Bernstein JL.

Br J Cancer. 2008 Feb 26;98(4):728-33. doi: 10.1038/sj.bjc.6604228. Epub 2008 Feb 5.

49.

The genome and epigenome of malignant melanoma.

Dahl C, Guldberg P.

APMIS. 2007 Oct;115(10):1161-76. Review.

PMID:
18042149
50.

Cancer genomics.

Norrild B, Guldberg P, Ralfkiaer E.

APMIS. 2007 Oct;115(10):1037-8.

PMID:
18042142

Supplemental Content

Loading ...
Support Center